Neurocrine Biosciences (NBIX) Amortizatization of Intangibles (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Amortizatization of Intangibles of $1.7 million for Q2 2026, down 50.0% year-over-year from $3.4 million in Q2 2025, and up 30.77% on a QoQ basis from $1.3 million in Q1 2026.
Neurocrine Biosciences (NBIX) Amortizatization of Intangibles (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Amortizatization of Intangibles for 17 years, with the latest figure at $1.7 million in Q2 2026.
- Amortizatization of Intangibles for Q2 2026 came in at $1.7 million, down 50.0% year-over-year; the trailing twelve-month figure through Jun 2026 was $7.7 million (down 61.69% YoY), and the FY2025 annual result was $12.7 million, down 51.53% from the prior year.
- Amortizatization of Intangibles improved to $1.7 million in Q2 2026, from $1.3 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $7.1 million in Q1 2024 and troughed at -$3.7 million in Q4 2022.
- A 5-year average of $3.8 million and a median of $3.9 million in 2023 frame the typical range for Amortizatization of Intangibles.
- The widest annual swing landed in 2022, when Amortizatization of Intangibles tumbled 190.24%; it then jumped 270.27% in 2023.
- A 5-year view of Amortizatization of Intangibles shows it stood at -$3.7 million in 2022, then jumped by 270.27% to $6.3 million in 2023, then retreated by 11.11% to $5.6 million in 2024, then tumbled by 64.29% to $2.0 million in 2025, then fell by 15.0% to $1.7 million in 2026.
- Per Business Quant data, the three most recent Amortizatization of Intangibles figures were $1.7 million in Q2 2026, $1.3 million in Q1 2026, and $2.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 900,000.00 |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.70 Mn |
| Jun 30, 2026 | 1.70 Mn |
| Mar 31, 2026 | 1.30 Mn |
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.70 Mn |
| Sep 30, 2025 | 2.70 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Mar 31, 2025 | 4.60 Mn |
| Mar 31, 2025 | 4.60 Mn |
| Dec 31, 2024 | 5.60 Mn |
| Dec 31, 2024 | 5.60 Mn |
| Sep 30, 2024 | 6.50 Mn |
| Sep 30, 2024 | 6.50 Mn |
| Jun 30, 2024 | 7.00 Mn |
| Jun 30, 2024 | 7.00 Mn |
| Mar 31, 2024 | 7.10 Mn |
| Mar 31, 2024 | 7.10 Mn |